Study: Proton Radiation Therapy in Treating Patients With Prostate Cancer
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
January 5th, 2010Clinical Trial Announcement
December 30th, 2009Study: Preoperative Radiation Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
December 24th, 2009Study: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
December 17th, 2009Study: Ketoconazole and Dexamethasone in Prostate Cancer (Keto/Dex)
Status: Recruiting
Sponsor: University of California, San Francisco
ClinicalTrials.gov Link: Click Here
Industry News
December 11th, 2009Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
Clinical Trial Announcement
December 7th, 2009Study: MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate
Status: Recruiting
Sponsor: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
December 3rd, 2009Study: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
November 30th, 2009Study: Abiraterone Acetate, Prednisone, and Leuprolide Acetate Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
November 24th, 2009Study: Hormone Therapy With or Without Bevacizumab in Treating Patients With Recurrent Prostate Cancer
Status: NOT YET Recruiting
Sponsor: Cancer Institute of New Jersey
ClinicalTrials.gov Link: Click Here
Clinical Trial Announcement
November 19th, 2009Study: Abiraterone Acetate Plus Prednisone Drug-Drug Interaction With Dextromethorphan and Theophylline Treating Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
Industry News
November 16th, 2009Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Breast Cancer Clinical Trial Results
November 11th, 2009Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Breast Cancer Clinical Trial Announcement
November 5th, 2009Study: ABT-888 and Temozolomide for Metastatic Breast Cancer
Brief Description:
The purpose of this research study is to find out if the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer. ABT-888 works by obstructing a DNA enzyme called poly (ADP-ribose) polymerase (PARP) which helps repair cancer cells damaged by chemotherapy. By blocking the PARP enzyme, the cancer cells are unable to repair themselves and as a result die. The other drug in this study is temozolomide. Temozolomide is designed to damage DNA in order to prevent cancer cells from reproducing. Because PARP inhibitors, such as ABT-888, prevent cancer cells from repairing their own DNA, they enhance the potential of chemotherapy therapy like temozolomide to induce cell death. The combination of ABT-888 and temozolomide has been used in a clinical trial for treatment of other cancers and information for this research study suggests that the combination may help to inhibit growth in breast cancer.
Status: Recruiting
Sponsor: Massachusetts General Hospital
ClinicalTrials.gov Link: Click Here
Breast Cancer Clinical Trial Results
November 4th, 2009Three-Week Course of Breast Radiation May Be as Effective as Conventional Five to Seven Week Course for Early Breast Cancers, Says U.S. Study
CHICAGO, Nov. 4 /PRNewswire-USNewswire/ — According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.
Industry News
November 4th, 2009Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival
Prostate Cancer Clinical Trial Results
November 3rd, 2009Shorter Radiation Course as Effective as Standard Therapy For Prostate Cancer Recurrence
Prostate Cancer Clinical Trial Results
November 3rd, 2009Shorter Radiation Course Stops Cancer Growth in High-Risk Prostate Cancer Patients
Clinical Trial Results
November 2nd, 2009Additional, Specialized Radiation Not Necessary for Some Women After Mastectomy
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ — After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Breast Cancer Clinical Trial Results
November 2nd, 2009Additional, Specialized Radiation Not Necessary for Some Women After Mastectomy
CHICAGO, Nov. 2 /PRNewswire-USNewswire/ — After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Breast Cancer Clinical Trial Announcement
November 2nd, 2009Study: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
Brief Description:
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free survival and over survival in HER2/neu positive women with locally advanced or metastatic breast cancer who are resistant to trastuzumab and have been pre-treated with a taxane.
Status: Recruiting
Sponsor: Novartis Pharmaceuticals
ClinicalTrials.gov Link: Click Here
Industry News
November 2nd, 2009Dendreon Completes Submission of Biologics License Application for PROVENGE
Prostate Cancer Clinical Trial Results
November 2nd, 2009Adding Proton Therapy ‘Boost’ to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences
Prostate Cancer Clinical Trial Results
November 2nd, 2009Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients
Clinical Trial Results
October 30th, 2009|
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ — Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. |
Breast Cancer Clinical Trial Announcement
October 26th, 2009Study: Nipple Sparing Mastectomy
Brief Description:
The purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex. These outcomes will be observed in patients with both known cancer diagnosis and in those with indications for prophylactic mastectomy. The cosmetic appearance and complications will be followed through several post operative visits throughout the duration of the study. This study is conducted in conjunction with the plastic and reconstructive surgeons who will be performing the breast reconstruction procedures. Patient satisfaction will be measured via survey format. In addition, local recurrence rates will be compared to patients undergoing traditional mastectomy
Status: Recruiting
Sponsor: Carolinas Healthcare System
ClinicalTrials.gov Link: Click Here
Clinical Trial Results
October 21st, 2009Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ — Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.
Breast Cancer Clinical Trial Announcement
October 9th, 2009Study: ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Brief Description:
The long-term objective of this research is to understand the molecular mechanisms of acquired endocrine resistance in breast cancer. Identifying these mechanisms is critical to the implementation of novel therapeutic strategies that can target and overcome altered gene networks involved in controlling breast cancer progression. While patients with tumors over expressing HER1, 2, or 3 have been shown to have reduced survival, patients with those tumors which overexpressed HER4 (erbB4) had increased survival (Witton 2003).
This is a non-randomized, single-arm, proof of principle trial. Selected are patients with advanced-stage breast cancer whose tumors are ER+, tamoxifen refractory. Histologically proven diagnosis of recurrent or metastatic breast cancer is advanced cancer for which there is no treatment available which would have a reasonable chance of cure. Treatment failure is defined as tumor progression after chemotherapy and tamoxifen therapy. Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose. Primary endpoints are measured by biopsy of palpable tumor with immunohistochemical staining for ERBB4. Secondary end points include the evaluation of cell death, apoptosis, with immunohistochemical staining for DNA breaks by TUNEL assay.
Status: Recruiting
Sponsor: Tulane University Health Sciences Center
ClinicalTrials.gov Link: Click Here
Breast Cancer Clinical Trial Announcement
October 7th, 2009Study: A Study of LY573636 in Patients With Metastatic Breast Cancer
Brief Description: The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636 for metastatic breast cancer.
Status: Recruiting
Sponsor: Eli Lilly and Company
ClinicalTrials.gov Link: Click Here
Industry News
October 6th, 2009FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
BOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with docetaxel for treatment of progressive metastatic prostate cancer following docetaxel.
Prostate Cancer Clinical Trial Results
October 1st, 2009Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 percent of patients at a median follow-up of two years. Published rates of erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, range from 50-70 percent.
Breast Cancer Clinical Trials Results
September 30th, 2009Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ — Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast cancer, demonstrated a positive trend towards improvement of progression-free survival in the treatment group (p-value=0.09). The safety and tolerability profile of the combination was consistent with the previous experience with each agent and no new toxicities were observed.
Prostate Cancer Clinical Trial Announcement
September 29th, 2009Study: A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer
Brief Description: The purpose of this study is to determine the safety and effectiveness of the study drug CNTO 888 in patients with metastatic castrate-resistant prostate cancer.
Status: Recruiting
Sponsor: Centocor, Inc.
ClinicalTrials.gov Link: Click Here
Breast Cancer Clinical Trial Announcement
September 29th, 2009Study: Vaccine Therapy in Treating Women With Triple-Negative Breast Cancer
Brief Description: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. This clinical trial is studying the side effects and how well vaccine therapy works in treating women with triple-negative breast cancer.
Status: Recruiting
Sponsor: Case Comprehensive Cancer Center
ClinicalTrials.gov Link: Click Here
Industry News
September 23rd, 2009Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
Industry News
September 23rd, 2009Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
Breast Cancer Clinical Trials Results
September 22nd, 2009Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Breast Cancer Clinical Trial Announcement
September 11th, 2009Study: Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Brief Description: This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment. Doxorubicin is a lifesaving breast cancer treatment. However, approximately 320% of women who receive doxorubicin treatment experience some damage to their heart muscle. Coenzyme Q10 is a fat soluble antioxidant dietary supplement that may protect against this heart damage during doxorubicin treatment. It is unknown how Coenzyme Q10 may interact with doxorubicin. This study will assess the effects of Coenzyme Q10 on doxorubicin metabolism.
Status: Recruiting
Sponsor: Columbia University
ClinicalTrials.gov Link: Click Here
Industry News
September 10th, 2009Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Industry News
September 10th, 2009Prostate Cancer Clinical Trial Announcement
September 9th, 2009Study: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
Brief Description: This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy
Status: Recruiting
Sponsor: Medivation, Inc.
ClinicalTrials.gov Link: Click Here
Breast Cancer Clinical Trial Announcement
September 3rd, 2009Study: Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade
Brief Description: The purpose of this research study is to find out more about distinguishing between cancerous and non-cancerous breast cancer cells at the edges of tumors. Using an FDA approved device to remove tumors, this device will be tested to see if it causes less tissue damage and therefore makes it easier to examine the tumor and make sure it is all excised. The tumors will be excised by standard surgical technique, and then the effects of the device on the removed tissues will be studied.
Status: Recruiting
Sponsor: University of California, San Diego
ClinicalTrials.gov Link: Click Here
Industry News
September 1st, 2009FDA Clears Hologic’s MammoSite(R) ML Radiation Therapy System for the Treatment of Early-Stage Breast Cancer
Prostate Cancer Clinical Trial Announcement
September 1st, 2009Study: Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer
Brief Description: The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer. The investigators will gather scientific information about the tolerance and side effects this type of radiation. The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.
Status: Recruiting
Sponsor: San Diego Radiosurgery
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
September 1st, 2009Study: Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy (PR06)
Brief Description: Patients are being asked to take part in this study because they had prostate cancer that was treated surgically and it has been determined that they might have a greater risk of their prostate cancer returning or their prostate cancer has already returned. The purpose of this study is to see what effects, good and/or bad, image guided proton based radiation therapy, and/or conventional radiation therapy and hormonal therapy (if applicable), has on the patient’s prostate cancer that has already returned or the risk of their prostate cancer returning. With the patient’s consent, this study will also look at their prostate cancer tissue that was removed during their surgery for information that may help to treat prostate cancer in the future.
Status: Recruiting
Sponsor: University of Florida
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Results
September 1st, 20092 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment
Industry News
August 27th, 2009Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
Advocacy/Support
August 24th, 2009Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals
Advocacy/Support
August 20th, 20095K ‘Dash for Dad’ Race Debuts in Buffalo During Prostate Cancer Awareness Month
Industry News
August 19th, 2009Results In ‘The New England Journal Of Medicine’ Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Breast Cancer Clinical Trial Announcement
August 11th, 2009Study: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
Brief Description: The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 4 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status
Status: Recruiting
Sponsor: Novartis
ClinicalTrials.gov Link: Click Here
Industry News
August 4th, 2009Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
Industry News
August 4th, 2009Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
Prostate Cancer Clinical Trial Announcement
July 29th, 2009Study: Active Surveillance for Cancer of the Prostate (ASCaP)
Brief Description: Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
Status: Recruiting
Sponsor: University of California, Los Angeles
ClinicalTrials.gov Link: Click Here
Industry News
July 28th, 2009Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
Prostate Cancer Clinical Trial Announcement
July 24th, 2009Study: Study Using WST11 In Patients With Localized Prostate Cancer (PCM202)
Brief Description: The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.
Status: Recruiting
Sponsor: Steba Biotech S.A.
ClinicalTrials.gov Link: Click Here
Industry News
July 22nd, 2009Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Prostate Cancer Clinical Trial Announcement
July 22nd, 2009Study: Pazopanib as Second Line Therapy in Patients With Prostate Cancer Refractory to Total Androgen Blockade
Status: Recruiting
Sponsor: Illinois CancerCare, P.C.
ClinicalTrials.gov Link: Click Here
Advocacy/Support
June 19th, 2009Soccer Hall of Famer Marcelo Balboa Encourages Men to ‘Team Up Against Prostate Cancer’
Prostate Cancer Clinical Trial Announcement
June 17th, 2009Study: Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer
Status: Recruiting
Sponsor: Beth Israel Medical Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
June 17th, 2009Study: Neoadjuvant Abiraterone Acetate plus leuprolide acetate in men with localized high risk prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment: July 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the “subscribe” link at the top of the page.
Prostate Cancer Clinical Trial Announcement
June 11th, 2009Study: Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsStatus: Recruiting
Status: Recruiting
Sponsor: Oncology Specialists, S.C., Wyeth
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
June 11th, 2009Study: Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg (CAMON)
Status: Recruiting
Sponsor: AstraZeneca
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
June 9th, 2009Study: Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-Resistant Prostate Cancer
Status: Recruiting
Sponsor: Weill Medical College of Cornell University
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
June 8th, 2009Study: Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)Status: Recruiting
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: Sanofi-Aventis
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
June 5th, 2009Study: Hypothermic Nerve Sparing Radical Prostatectomy
Status: Recruiting (by invitation)
Sponsor: University of California, Irvine
ClinicalTrials.gov Link: Click Here
Industry News
June 2nd, 2009Medivation announces positive new efficacy data from Phase 1-2 trial of MDV3100 in advanced prostate cancer patients
Prostate Cancer Clinical Trial Announcement
June 1st, 2009Study: Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Status: Recruiting
Sponsor: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
June 1st, 2009Study: QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate
Status: Recruiting
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
Industry News
June 1st, 2009Ascenta Therapeutics announces presentation of promising results from clinical trials of AT-101 in prostate, brain, and lung cancers at 2009 ASCO annual meeting
Industry News
June 1st, 2009AEtna Zentaris presents data supporting evaluation of AEZS-108 in prostate cancer at ASCO meeting
Industry News
June 1st, 2009PROSTVAC data presented at ASCO meeting demonstrates the potential for significant increases in life expectancy in late-state prostate cancer
Industry News
May 30th, 2009OncoGenex Pharmaceuticals announces OGX-011 treatment provides survival benefit in randomized Phase 2 trial in advanced metastatic prostate cancer
Industry News
May 28th, 2009Poniard Pharmaceuticals announces positive efficacy and safety data from Phase 2 clinical trial of Picoplatin in men with metastatic prostate cancer
Prostate Cancer Clinical Trial Announcement
May 26th, 2009Study: GM-CSF in Treating Patients With Relapsed Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: Unknown
Sponsor: The Cleveland Clinic, National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
May 26th, 2009Study: Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
Status: Recruiting
Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
May 22nd, 2009Study: RNActive®-Derived Therapeutic Vaccine
Status: Recruiting
Sponsor: University of Florida, CureVac GmbH
ClinicalTrials.gov Link: Click Here
Prostate Cancer Clinical Trial Announcement
May 7th, 2009Study: Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC)
Status: Not yet recruiting*
Anticipated start of recruitment: August 2009
Sponsor: Dendreon
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Advocacy/Support
May 6th, 2009Team ZERO to Run to End Prostate Cancer in 2009 ING New York City Marathon:
CTAG News
May 5th, 2009Clinical Trials Advocacy Group for Prostate Cancer partners with “Prostate Cancer InfoLink”
Prostate Cancer InfoLink “offering the most user-friendly personalized prostate cancer information on the web” has agreed to feature CTAG for Prostate Cancer as its default search tool for prostate cancer clinical trials.
To view the Prostate Cancer InfoLink webpage Click Here
Industry News
April 28th, 2009OncoGenex receives confirmation from FDA on the design of a second Phase 3 trial evaluating OGX-011 for the treatment of advanced prostate cancer:
Industry News
April 28th, 2009Data presented at AUA demonstrate PROVENGE significantly prolongs survival for men with advanced prostate cancer in pivotal Phase 3 IMPACT study:
Industry News
April 27th, 2009Ferring Pharmaceuticals launches Phase IIIB trial of Degarelix as intermittent therapy:
Prostate Cancer Clinical Trial Announcement
April 24th, 2009Study: Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting*
Anticipated start of recruitment: March 2009
Sponsor: Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
April 23rd, 2009Study: Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Status: Not yet recruiting*
Anticipated start of recruitment: July 2009
Sponsor: Duke University
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
April 18th, 2009Study: Abiraterone Acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer
Status: Not yet recruiting*
Anticipated start or recruitment: April 2009
Sponsor: Cougar Biotechnology
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Prostate Cancer Clinical Trial Announcement
April 17th, 2009Study: Investigation of the effect of Degarelix in terms of prostate volume reduction in prostate cancer patients
Status: Not yet recruiting*
Anticipated start of recruitment: May 2009
Sponsor: Ferring Pharmaceuticals
ClinicalTrials.gov Link: Click Here
* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.
Industry News
March 31st, 2009Stanford study on CyberKnife Radiosurgery for prostate cancer demonstrates 100 percent PSA response at 33 months: